Market Overview:
The global tinea corporis drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of tinea corporis, rising awareness about available treatment options, and growing demand for combination therapies. The global tinea corporis drugs market is segmented on the basis of type into antifungals, steroids, and anti-infective combinations. The antifungal segment is expected to dominate the market during the forecast period owing to their high efficacy in treating tinea corporis infections. On the basis of application, the hospital pharmacies segment is expected to account for a major share of the global market during the forecast period as hospitals are often preferred by patients suffering from serious or life-threatening infections. However, with increasing demand for self-medication and growing availability of drugs through retail pharmacies and online pharmacies, this trend is likely to change in favor of these latter segments over time.
Product Definition:
Tinea corporis is a skin infection caused by a fungus. The most common type of fungus that causes this infection is called dermatophytes. Tinea corporis can be treated with antifungal drugs, such as terbinafine (Lamisil), itraconazole (Sporanox), or fluconazole (Diflucan).
Antifungals:
Antifungals is a group of medicines used to treat fungal infections. Fungal infection includes athlete's foot, ringworm, jock itch and other skin infections.
Steroids:
Steroids are man-made chemicals that are extracted from animal or plant sources and used as a medication for the treatment of various skin diseases. They have anti-inflammatory properties which help in reducing itching and inflammation. Steroids can be administered in several forms such as topical, oral, injectable or by means of creams, lotions or gels.
Application Insights:
The hospital pharmacies segment held the largest market share in 2017. This is due to a high prevalence of tinea corporis and increasing awareness among consumers regarding availability of affordable drugs in the hospital pharmacy. In addition, growing government initiatives against fungal infections are also expected to contribute towards revenue generation for this segment over the forecast period.
The retail pharmacies accounted for a significant share owing to high accessibility and availability of antifungal creams at an affordable price range as compared with other pharmaceutical products available in the market place. Retailers offer huge discounts on purchasing large quantities which attracts consumers towards purchasing these drugs from them instead buying it from other sources such as online pharmacies or hospitals, thereby generating higher revenue for this segment than others over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high healthcare expenditure levels in this region is anticipated to drive the regional market further. In addition, increasing prevalence of onychomycosis due to changing lifestyle habits such as spending more time indoors and exposure to artificial lighting is expected to propel growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing its huge population base, rising disposable income levels, improving healthcare infrastructure along with growing awareness about available treatment options for tinea corporis conditions among patients are some factors driving regional growth.
Growth Factors:
- Increasing incidence of tinea corporis due to changing lifestyle and increasing population
- Rising awareness about the treatment and diagnosis of tinea corporis
- Growing demand for better-tolerated antifungal drugs
- Technological advancements in drug delivery systems
- Availability of generic versions of branded drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Tinea Corporis Drugs Market Research Report
By Type
Antifungals, Steroids, Anti-Infective Combinations
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Sun Pharmaceutical, Teva, Glenmark, Aurobindo, AvKare, Novartis, Sebela, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Tinea Corporis Drugs Market Report Segments:
The global Tinea Corporis Drugs market is segmented on the basis of:
Types
Antifungals, Steroids, Anti-Infective Combinations
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sun Pharmaceutical
- Teva
- Glenmark
- Aurobindo
- AvKare
- Novartis
- Sebela
- Bayer
Highlights of The Tinea Corporis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antifungals
- Steroids
- Anti-Infective Combinations
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tinea Corporis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tinea corporis is a skin infection caused by fungi. Common fungal infections of the skin include tinea pedis (foot fungus), tinea cruris (jock itch), and tinea versicolor (pityriasis versicolor). Drugs used to treat these infections include antifungal creams, oral antibiotics, and systemic steroids.
Some of the key players operating in the tinea corporis drugs market are Sun Pharmaceutical, Teva, Glenmark, Aurobindo, AvKare, Novartis, Sebela, Bayer.
The tinea corporis drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tinea Corporis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tinea Corporis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tinea Corporis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tinea Corporis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tinea Corporis Drugs Market Size & Forecast, 2018-2028
4.5.1 Tinea Corporis Drugs Market Size and Y-o-Y Growth
4.5.2 Tinea Corporis Drugs Market Absolute $ Opportunity
Chapter 5 Global Tinea Corporis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tinea Corporis Drugs Market Size Forecast by Type
5.2.1 Antifungals
5.2.2 Steroids
5.2.3 Anti-Infective Combinations
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tinea Corporis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tinea Corporis Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tinea Corporis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tinea Corporis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tinea Corporis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Tinea Corporis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tinea Corporis Drugs Market Size Forecast by Type
9.6.1 Antifungals
9.6.2 Steroids
9.6.3 Anti-Infective Combinations
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tinea Corporis Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tinea Corporis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Tinea Corporis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tinea Corporis Drugs Market Size Forecast by Type
10.6.1 Antifungals
10.6.2 Steroids
10.6.3 Anti-Infective Combinations
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tinea Corporis Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tinea Corporis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tinea Corporis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tinea Corporis Drugs Market Size Forecast by Type
11.6.1 Antifungals
11.6.2 Steroids
11.6.3 Anti-Infective Combinations
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tinea Corporis Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tinea Corporis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Tinea Corporis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tinea Corporis Drugs Market Size Forecast by Type
12.6.1 Antifungals
12.6.2 Steroids
12.6.3 Anti-Infective Combinations
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tinea Corporis Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tinea Corporis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tinea Corporis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tinea Corporis Drugs Market Size Forecast by Type
13.6.1 Antifungals
13.6.2 Steroids
13.6.3 Anti-Infective Combinations
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tinea Corporis Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tinea Corporis Drugs Market: Competitive Dashboard
14.2 Global Tinea Corporis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sun Pharmaceutical
14.3.2 Teva
14.3.3 Glenmark
14.3.4 Aurobindo
14.3.5 AvKare
14.3.6 Novartis
14.3.7 Sebela
14.3.8 Bayer
